Progressive tumor formation in mice with conditional deletion of TGF-β signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway

Cancer Research

Volumn 69, Issue 14, 2009, Pages 5918-5926

  Bian, Yansong ^a   Terse, Anita ^a   Du, Juan ^a   Hall, Bradford ^a   Molinolo, Alfredo ^a   Zhang, Pin ^a   Chen, Wanjun ^a   Flanders, Kathleen C ^b   Gutkind, J Silvio ^a   Wakefield, Lalage M ^b   Kulkarni, Ashok B ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; DIMETHYLBENZ[A]ANTHRACENE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMAD2 PROTEIN; SMAD3 PROTEIN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HEAD AND NECK CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH;

1-PHOSPHATIDYLINOSITOL 3-KINASE; 9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL PROLIFERATION; ENZYME ACTIVATION; EPITHELIUM; FEMALE; GENE DELETION; HEAD AND NECK NEOPLASMS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 67650999753     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4623     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Kim MM, Califano JA. Molecular pathology of head-and-neck cancer. Int J Cancer 2004;112:545-53.
3. Mao L, Hong WK, Papadimitrakopoulou VA. Focus on head and neck cancer. Cancer Cell 2004;5:311-6.
4. Lu SL, Reh D, Li AG, et al. Overexpression of transforming growthf actor β1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Res 2004;64:4405-10.
5. Qiu W, Schönleben F, Li X, Su GH. Disruption of transforming growthfactor h-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4. Cancer Lett 2007;245:163-70.
6. Roberts AB, Wakefield LM. The two faces of transforming growthfactor h in carcinogenesis. Proc Natl Acad Sci U S A 2003;100:8621-3.
7. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-β family signaling. Nature 2003;425:577-84.
8. Massagué J. TGF-β in cancer. Cell 2008;134:215-30.
9. Engle SJ, Hoying JB, Boivin GP, Ormsby I, Gartside PS, Doetschman T. Transforming growth factor β1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res 1999;59:3379-86.
10. Piek E, Roberts AB. Suppressor and oncogenic roles of transforming growth factor-β and its signaling pathways in tumorigenesis. Adv Cancer Res 2001;83:1-54.
11. Tang B, Vu M, Booker T, et al. TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 2003;112:1116-24.
12. Xie W, Bharathy S, Kim D, Haffty BG, Rimm DL, Reiss M. Frequent alterations of Smad signaling in human head and neck squamous cell carcinomas: a tissue microarray analysis. Oncol Res 2003;14:61-73.
13. Huntley SP, Davies M, Matthews JB, et al. Attenuated type II TGF-β receptor signaling in human malignant oral keratinocytes induces a less differentiated and more aggressive phenotype that is associated withmeta static dissemination. Int J Cancer 2004;110:170-6.
14. Lu SL, Herrington H, Reh D, et al. Loss of transforming growth factor-β type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev 2006;20:1331-42.
15. Chen T, Yan W, Wells RG, et al. Novel inactivating mutations of transforming growthf actor-β type I receptor gene in head-and-neck cancer metastases. Int J Cancer 2001;93:653-61.
16. Knobloch TJ, Lynch MA, Song H, et al. Analysis of TGF-β type I receptor for mutations and polymorphisms in head and neck cancers. Mutat Res 2001;479:131-9.
17. Pasche B, Knobloch TJ, Bian Y, et al. Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA 2005;294:1634-46.
18. Larsson J, Goumans MJ, Sjöstrand LJ, et al. Abnormal angiogenesis but intact hematopoietic potential in TGF-β type I receptor-deficient mice. EMBO J 2001;20:1663-73.
19. Honjo Y, Bian Y, Kawakami K, et al. TGF-β receptor I conditional knockout mice develop spontaneous squamous cell carcinoma. Cell Cycle 2007;6:1360-6.
20. Vasioukhin V, Degenstein L, Wise B, Fuchs E. The magical touch: genome targeting in epidermal stem cells induced by tamoxifen application to mouse skin. Proc Natl Acad Sci U S A 1999;96:8551-6.
21. Czerninski R, Amornphimoltham P, Patel V, Molinolo AA, Gutkind JS. Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model. Cancer Prev Res 2009;2:27-36.
22. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
23. + regulatory T cells. Nat Immunol 2008;9:632-40.
24. Kim TW, Chen Q, Shen X, et al. Oral mucosal carcinogenesis in SENCAR mice. Anticancer Res 2002;22:2733-40.
25. Chen Z, Malhotra PS, Thomas GR, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 1999;5:1369-79.
26. Goulart Filho JA, Nonaka CF, da Costa Miguel MC, de Almeida Freitas R, Galvão HC. Immunoexpression of cyclooxygenase-2 and p53 in oral squamous cell carcinoma. Am J Otolaryngol 2009;30:89-94.
27. Wikström P, Lissbrant IF, Stattin P, Egevad L, Bergh A. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 2002;51:268-75.
28. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growtha nd angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005;121:335-48.
29. Lewis MP, Lygoe KA, Nystrom ML, et al. Tumour-derived TGF-β1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells. Br J Cancer 2004;90:822-32.
30. Smyth MJ, Dunn GP, Schreiber RD. Cancer immuno-surveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006;90:1-50.
31. Kim BG, Li C, Qiao W, et al. Smad4 signaling in T cells is required for suppression of gastrointestinal cancer. Nature 2006;441:1015-9.
32. Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 2008;45:324-34.
33. Eng C. PTEN: one gene, many syndromes. Hum Mutat 2003;22:183-98.
34. Massagué J, Gomis RR. The logic of TGF-β signaling. FEBS Lett 2006;580:2811-20.
35. Levy L, Hill CS. Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 2006;17:41-58.
36. Bierie B, Moses HL. Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006;6:506-20.
37. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massagué J. Transforming growthfactor h signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci U S A 2003;100:8430-5.
38. Bhowmick NA, Chytil A, Plieth D, et al. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004;303:848-51.
39. Ijichi H, Chytil A, Gorska AE, et al. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-β signaling in cooperation with active Kras expression. Genes Dev 2006;20:3147-60.
40. Guasch G, Schober M, Pasolli HA, Conn EB, Polak L, Fuchs E. Loss of TGFβ signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia. Cancer Cell 2007;12:313-27.
41. Biswas S, Chytil A, Washington K, et al. Transforming growth factor β receptor type II inactivation promotes the establishment and progression of colon cancer. Cancer Res 2004;64:4687-92.
42. Bierie B, Stover DG, Abel TW, et al. Transforming growth factor-β regulates mammary carcinoma cell survival and interaction withth e adjacent microenvironment. Cancer Res 2008;68:1809-19.
43. Feng XH, Derynck R. Specificity and versatility in tgf-β signaling through Smads. Annu Rev Cell Dev Biol 2005;21:659-93.
44. Daly AC, Randall RA, Hill CS. Transforming growth factor h-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth. Mol Cell Biol 2008;28:6889-902.
45. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-β type I receptors. EMBO J 2002;21:1743-53.
46. Ozdamar B, Bose R, Barrios-Rodiles M, Wang HR, Zhang Y, Wrana JL. Regulation of the polarity protein Par6 by TGFβ receptors controls epithelial cell plasticity. Science 2005;307:1603-9.
47. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003;200:429-47.
48. Go C, Li P, Wang XJ. Blocking transforming growth factor β signaling in transgenic epidermis accelerates chemical carcinogenesis: a mechanism associated with increased angiogenesis. Cancer Res 1999;59:2861-8.
49. Wang J, Yang L, Yang J, et al. Transforming growth factor h induces apoptosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells. Cancer Res 2008;68:3152-60.